Patient-Reported Outcomes from the CARTITUDE-4 Study Showed Clinically Meaningful Improvements in He

In CARTITUDE-4, CARVYKTI® demonstrated clinically meaningful improvements in patient-reported outcomes when compared to standard of careThe as-treated population in CARTITUDE-4 demonstrated strong rates of progression-free survival and overall responseLonger-term data from CARTITUDE-2 showed deep and durable respons...

Related Keywords

United States ,Italy ,American ,Ying Huang ,Alexandra Ventura ,Jessie Yeung ,Roberto Mina ,University Of Torino ,Corporate Communications Investor Relations ,Department Of Molecular Biotechnology ,Clinical Development ,Health Sciences ,European Organisation For Research ,American Society Of Hematology ,Division Of Hematology ,Janssen Biotech Inc ,Legend Biotech Corporation ,Legend Biotech ,Annual Meeting ,Assistant Professor ,Molecular Biotechnology ,European Organisation ,Cancer Quality ,Life Questionnaire Core ,Multiple Myeloma Symptom ,Impact Questionnaire ,Cytokine Release Syndrome ,Chief Executive Officer ,Important Safety ,Release Syndrome ,Effector Cell Associated Neurotoxicity Syndrome ,Macrophage Activation Syndrome ,Risk Evaluation ,Mitigation Strategy ,Nerve Palsies ,Janssen Biotech ,Prescribing Information ,Boxed Warning ,Corporate Communications ,Investor Relations ,Public Relations ,